<DOC>
	<DOCNO>NCT02038036</DOCNO>
	<brief_summary>This trial compare efficacy safety ruxolitinib Best Available Therapy ( BAT ) patient polycythemia vera ( PV ) hyroxyurea ( HU ) resistant intolerant palpable spleen .</brief_summary>
	<brief_title>Ruxolitinib Efficacy Safety Patients With HU Resistant Intolerant Polycythemia Vera v Best Available Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Confirmed diagnosis PV accord 2008 World Health Organization criterion , Nonpalpable spleen , Phlebotomy dependent , Resistant intolerant hydroxyurea , ECOG performance status 0 , 1 2 . Inadequate liver renal function , Significant bacterial , fungal , parasitic , viral infection require treatment , Active malignancy within past 5 year , exclude specific skin cancer , Previously receive treatment JAK inhibitor , Being treat investigational agent , Women pregnant nursing . Other inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>INC424</keyword>
	<keyword>Ruxolitinib</keyword>
</DOC>